Navigation Links
Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Date:6/22/2013

erience will be consistent with study findings to date or that empagliflozin* will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

CONTACT:

Catherine London
Associate Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: usnews@boehringer-ingelheim.com
Phone: (203) 798-4638

Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: (317) 651-9116

References

  1. Haring H, et al. Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients with Type 2 diabetes (T2DM). Poster No: 1092-P. Presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®. June 21-25, Chicago, IL.
  2. Haring H, et al. Empagliflozin as Add-On to Metformin Plus Sulfonylurea (SU) for 24 Weeks Improves Glycemic Control in Patients with Type 2 diabetes (T2DM). Poster No: 1082-P. Presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®. June 21-25, Chicago, IL.
  3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Center for Disease Control and Prevention, 2011.
  4. International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact Sheet. 2012.
  5. International Diabetes Feder
    '/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... , CAMBRIDGE, Mass., Oct. 14 Northern Light ( ... EBSCO Publishing (EBSCO) ( www.ebscohost.com ) that ... than 4,000 bio-pharmaceutical, health sciences and general business magazines, ... strategic research portals. SinglePoint users who also subscribe ...
... Luminous Medical, Inc. announced today that it has ... for exclusive rights to incorporate its glucose sensor into ... its monitor to enable clinicians to control hyperglycemia in ... was planning to use a sensing technology based on ...
Cached Medicine Technology:Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 2Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 3Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor 2
(Date:4/24/2014)... Philadelphia, Pa. (April 24, 2014) - Contact lenses coated with ... contact lens-related infections, reports a study in Optometry ... American Academy of Optometry . The journal is published ... Wolters Kluwer Health . , Studies in animals and ... with the antimicrobial peptide melimine, according to the new research ...
(Date:4/24/2014)... be boring and irrelevant, could offer an alternative to ... Dr Milena Furtado, and her team from the Australian ... heart cell fibroblast is a close relative to a ... , In research published today in Circulation Research ... unique cells due to their genetic program, and will ...
(Date:4/24/2014)... in the world to discover a gene mutation in ... Ameloblastoma is an odontogenic tumour with a high tendency ... in the posterior of the lower jaw. Ameoloblastomas are ... the jaws as well as loss of several teeth. ... surgery and the recurrence of ameloblastoma, but finding such ...
(Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
(Date:4/23/2014)... Spokane have developed a new way to detect ... the wheel. , Their recently patented technology is ... in drowsy driversand offers an affordable and more ... detection systems. , Van Dongen"Video-based systems that use ... out of its lane are cumbersome and expensive," ...
Breaking Medicine News(10 mins):Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2
... Goodwin HealthDay Reporter , WEDNESDAY, Feb. 9 ... cancer cell genome revealed never-before-seen changes in DNA that ... By mapping the full genetic blueprint of the tumor, ... development of more targeted drugs and a better understanding ...
... Salamon HealthDay Reporter , WEDNESDAY, Feb. 9 ... than doubled the progression-free survival time for patients with ... new studies. In separate phase 3 trials by ... extended the survival of participants with advanced pancreatic neuroendocrine ...
... parks and recreation sites may be healthier, more physically ... to Penn State researchers. Investments in parks and recreational ... say Geof Godbey, professor emeritus of leisure studies, and ... "There is a strong relationship between how much money ...
... Feb. 9 (HealthDay News) -- About one in 10 ... after. Though typically harmless, some may need treatment because ... "There are several different types of birthmarks, so it ... considering any possible treatments," dermatologist Dr. Sheila Fallon Friedlander, ...
... diagnose heart disease, cancers, HIV and other diseases quickly ... The microsponges are an essential component of Rice University,s ... paper in the journal Small . ... Bioengineering and Chemistry, and his colleagues at Rice,s BioScience ...
... plan from an arm of the National Institutes of ... of most single-gene disorders and gaining new insights into ... to more accurate diagnoses, new drug targets and the ... therapeutic options, according to the plan from the National ...
Cached Medicine News:Health News:First Look at Prostate Cancer Genome Yields Insights 2Health News:First Look at Prostate Cancer Genome Yields Insights 3Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 2Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 3Health News:Key to better health care may be a walk in the park 2Health News:Not All Birthmarks Harmless, Expert Says 2Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:NHGRI charts course for the next phase of genomics research 2Health News:NHGRI charts course for the next phase of genomics research 3Health News:NHGRI charts course for the next phase of genomics research 4
The Precedent establishes a new generation of revision hip stems....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
...
...
Medicine Products: